For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for The Travelers Companies, Inc. (TRV) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-08): Designation Watch · Gem Score -10 (−100…+100 Quality+Value blend) · Quality 67 · Value -62 · Sentiment 41 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
The Travelers Companies, Inc.
TRV NYSEThe Travelers Companies, Inc. is a leading American property and casualty insurance holding company headquartered in New York, New York. The company provides a broad range of insurance products designed to protect individuals, businesses, and organizations from risk. Its operations are organized into three main segments: Business Insurance, offering commercial property, casualty, and workers’ compensation coverage; Bond and Specialty Insurance, providing surety, management liability, and professional liability solutions; and Personal Insurance, focused on auto, homeowners, and other personal lines. Travelers distributes its products primarily through independent agents and brokers, serving customers across the United States and selected international markets. The company plays a significant role in the insurance sector by helping manage and transfer risk for small, mid-sized, and large enterprises as well as individual policyholders, supporting financial stability and resilience across the economy.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 27.43
Total Equity: $32.89B
Shares: 229,238,061
Total Debt: $300.00M
Cash: $842.00M
EBITDA: N/A
Total Debt: $300.00M
Cash: $842.00M
Revenue: $48.83B
Revenue: $48.83B
Revenue: $48.83B
Total Equity: $32.89B
Tax Rate: 19.3%
Equity: $32.89B
Total Debt: $300.00M
Cash: $842.00M
Current Liabilities: N/A
Long-Term Debt: $0.00
Total Debt: $300.00M
Total Equity: $32.89B
Shares: 229,238,061
Shares: 229,238,061
CapEx: $0.00
Shares: 229,238,061
Stock Price: $376.42
Net Income: $6.29B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 11, 2026 12:02pm (58d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $34.8B | $36.9B | $41.4B | $46.4B | $48.8B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $4.7B | $4.8B | $5.2B | $5.8B | $6.1B |
| Operating Income | — | — | — | — | — |
| Net Income | $3.7B | $2.8B | $3.0B | $5.0B | $6.3B |
| EBITDA | — | — | — | — | — |
| EPS | $14.63 | $11.91 | $12.93 | $21.76 | $27.83 |
| EPS (Diluted) | $14.49 | $11.77 | $12.79 | $21.47 | $27.43 |
Balance Sheet (Annual)
Last updated: Aug 11, 2026 11:34am (58d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $761.0M | $799.0M | $650.0M | $699.0M | $842.0M |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $120.5B | $115.7B | $126.0B | $133.2B | $143.7B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $91.6B | $94.2B | $101.1B | $105.3B | $110.8B |
| Total Equity | $28.9B | $21.6B | $24.9B | $27.9B | $32.9B |
| Retained Earnings | $41.6B | $43.5B | $45.6B | $49.6B | $54.9B |
Cash Flow (Annual)
Last updated: Aug 11, 2026 12:02pm (58d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7.3B | $6.5B | $7.7B | $9.1B | $10.6B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | -$38.0M | -$4.0M | $0 | -$382.0M | $0 |
| Net Debt Issued / (Repaid) | $0 | $0 | — | — | — |
| Dividends Paid | -$869.0M | -$875.0M | -$908.0M | -$951.0M | -$979.0M |
| Stock Buybacks | -$2.2B | -$2.0B | -$958.0M | -$1.0B | -$3.0B |
| Net Change in Cash | $40.0M | $38.0M | -$149.0M | $49.0M | $314.0M |
Growth Trends (YoY %)
Last updated: Aug 11, 2026 12:02pm (58d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +6.0% | +12.1% | +12.2% | +5.2% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | -22.4% | +5.2% | +67.1% | +25.8% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Aug 11, 2026 11:35am (58d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-10 | $1.25 | — | — | — |
| 2026-03-10 | $1.10 | — | — | — |
| 2025-12-10 | $1.10 | — | — | — |
| 2025-09-10 | $1.10 | — | — | — |
| 2025-06-10 | $1.10 | — | — | — |
| 2025-03-10 | $1.05 | — | — | — |
| 2024-12-10 | $1.05 | — | — | — |
| 2024-09-10 | $1.05 | — | — | — |
| 2024-06-10 | $1.05 | — | — | — |
| 2024-03-07 | $1.00 | — | — | — |
| 2023-12-07 | $1.00 | — | — | — |
| 2023-09-07 | $1.00 | — | — | — |
| 2023-06-08 | $1.00 | — | — | — |
| 2023-03-09 | $0.93 | — | — | — |
| 2022-12-08 | $0.93 | — | — | — |
| 2022-09-08 | $0.93 | — | — | — |
| 2022-06-09 | $0.93 | — | — | — |
| 2022-03-09 | $0.88 | — | — | — |
| 2021-12-09 | $0.88 | — | — | — |
| 2021-09-09 | $0.88 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Not computed yetNarrative Economics
market-narrative step).
Claude Reading
The raw numbers tell a cleaner story than the models suggest. TTM revenue is roughly $48.97B (Q3'25 through Q2'26), with net income of $8.31B — that's a 17.0% net margin, well above the 12.9% annual figure the canonical metrics still cite. The last four quarters show margins of 15.1%, 20.1%, 14.3%, 18.2% — not a single quarter below 14%, versus Q1'25's 3.3% wipeout (Southern California wildfires, presumably). At $376 and ~208M shares, this is roughly a 9.4x TTM P/E, not the 13.7x the FMP data tags. Book value ~$32.9B implies P/B of ~2.38x, not 2.62x. ROE on trailing earnings is ~25%, not 19%. The models are anchoring on stale annual figures and missing that the last four quarters have been materially better than 2024 or 2023.
That said, the skeptic in me notes the obvious: 17% net margins for a P&C insurer are peak-cycle, not mid-cycle. The 45% earnings CAGR is arithmetic off a depressed 2022 base ($2.84B NI) — meaningless as a forward indicator. Reserve releases, benign cat quarters, and a fat investment yield curve (Travelers' bond book is finally rolling into 5%+ paper) are all tailwinds that mean-revert. Combined ratios in the low 90s don't hold forever — the long-run industry average is 98-100. If you normalize net margin to 11-12% (a reasonable through-cycle number) on ~$50B revenue, you get ~$5.7B earnings, or ~$27/share, and at a 13-14x mature-insurer multiple that's $350-380. So the current price is roughly fair on normalized earnings, expensive on peak, cheap on trailing. The synthesis's $307 fair value looks too punitive — it appears to assume immediate reversion without giving credit to the structurally higher investment income base (~$10.6B operating CF, up materially from prior years as the portfolio re-yields).
Where I diverge from the models: the thesis-evaluation headline ("priced for stagnation") is wrong on the multiple — 9.4x trailing is genuinely cheap, but trailing includes peak underwriting, so the "cheapness" is illusory. The synthesis's "fully priced" is directionally right but for the wrong reason — it's not that the market prices in too much growth (growth isn't the story), it's that the market may be extrapolating peak underwriting margins. Narrative Economics' framing of a "22% premium to DCF" also feels overconfident given DCF on a cyclical insurer is a spreadsheet exercise with 30% error bars. Insider activity is uniformly sell-side option exercises — routine, not a signal, but also not the "diamond hands" you'd want if insiders thought $376 was a steal. Debt/equity of 0.009 is basically noise; the real leverage is the investment portfolio, which the summary tables don't show.
A careful contrarian would argue: (1) 2025 cat losses were front-loaded into Q1 ($395M NI quarter — that's the LA fires); the rest of 2025 and H1'26 were unusually benign, and 2026 hurricane season isn't done. One bad Q3 could take a $2B quarter to $800M. (2) Commercial P&C rate momentum is decelerating per industry data — Marsh's rate index has been softening for four quarters. (3) Investment income tailwind is largely booked; incremental gains from here require the curve to stay elevated, which is a macro bet. Verdict: I disagree with the synthesis's $307 fair value as too bearish and disagree with the thesis-eval bull framing as too rosy. Fair value is $340-370 on normalized ~$28-30 EPS at 12-13x, meaning TRV at $376 is modestly rich but not egregiously so. Not a short, not a buy — a hold with a reload point in the $310s if a bad cat quarter creates dislocation. The models are collectively too pessimistic on the balance sheet quality and too optimistic on the durability of peak margins, and they cancel out roughly at the current price.
GPT Reading
Travelers looks like an excellent insurer and a mediocre stock at this price. The operating data are undeniably strong: revenue rose from $34.8B in 2021 to $48.8B in 2025, a roughly 40% increase in four years, while net income climbed from $3.66B to $6.29B despite the inherent noise of catastrophe-heavy P&C results. The latest four quarters are even better than the annual summary suggests: from 3Q24 through 2Q26, quarterly net income ran between $1.26B and $2.50B in seven of eight quarters, with only 1Q25 dipping to $395M. That pattern tells me this is not a fragile earnings story dependent on one lucky quarter; underwriting and investment income are both carrying more weight than they did a few years ago. ROE at 19.1% with essentially no leverage is a real quality signal, and $10.6B of operating cash flow against only $300M of debt underscores just how conservative the balance sheet is.
But the stock is being valued more like a premium compounder than a cyclical insurer. At $376, the market cap is $78.3B against year-end equity of $32.9B, so investors are paying about 2.6x book for a business that, while high-quality, still lives in a pricing cycle and remains exposed to catastrophe volatility. On 2025 earnings the stock trades at 13.7x, which is not absurd in isolation, but it is full for an insurer after earnings have already inflected from $2.99B in 2023 to $5.00B in 2024 and $6.29B in 2025. Annual revenue growth has also slowed from the post-2022 surge to something closer to mid-single digits in the recent quarterly run rate: 2Q26 revenue of $12.15B was only 0.2% above 2Q25’s $12.12B, and 1Q26’s $11.92B was just 0.9% above 1Q25’s $11.81B. So while earnings remain robust, top-line momentum is flattening, which matters because this valuation really needs sustained margin strength, not just stability.
The key issue is mean reversion risk. Travelers has earned net margins of 12.5% to 20.1% in five of the last six quarters after posting just 3.3% in 1Q25; that swing is a reminder that “normal” earnings power in P&C is never as smooth as the trailing P/E suggests. If catastrophe losses are merely average-to-bad rather than benign, or if commercial pricing stops outrunning loss-cost inflation, the current earnings base can slip faster than the market is pricing. A 19% ROE franchise deserves a premium to book, but 2.6x book implies confidence that Travelers can hold near-peak profitability for years. I don’t see enough in the revenue trajectory to justify that confidence. This feels like a stock where the business can keep executing and the shares still underperform because expectations are already calibrated to a near-best-case underwriting environment.
The best pushback is that I may be overemphasizing cyclicality and underestimating structural improvement. The company has gone from $2.84B-$3.66B of annual earnings in 2021-2022 to $5.00B-$6.29B in 2024-2025, and the latest two quarters delivered $3.92B combined net income on $24.1B of revenue, an exceptional run that suggests stronger normalized earnings than old-cycle comparables would imply. With debt-to-equity of just 0.009, Travelers has enormous balance-sheet flexibility, and the payout ratio of 15.6% leaves room for sustained buybacks and dividend growth. If investment income remains structurally higher because rates stay elevated, then a low-teens earnings multiple may not be demanding at all. I also take seriously that insurers with discipline and agent-channel strength often deserve to sit above “commodity” peer valuations for long stretches.
What would change my mind is either a better price or more proof that the earnings base has genuinely reset upward. At roughly $300-$320, the valuation would better compensate for catastrophe and cycle risk, especially if book value continues compounding. Alternatively, I would get more constructive even near today’s price if the next few quarters show revenue reaccelerating above 5%-6% while net income stays above roughly $1.7B per quarter through a less favorable loss environment; that would support the case that Travelers is not just benefiting from a cyclical peak. On the other hand, if quarterly earnings fall back toward the 2023 run-rate without a corresponding drop in valuation, the premium multiple will look plainly unjustified.
Grok Reading
The numbers describe a high-quality P&C franchise that has already harvested most of the easy earnings recovery. Revenue climbed from $34.8B in 2021 to $48.8B in 2025, an 8.6% CAGR, while net income more than doubled from the $2.8–3.0B trough years to $6.29B. That 45% earnings CAGR is real but mechanical: it is the unwind of catastrophe-heavy years plus hard-market pricing and higher reinvestment yields, not a permanent step-change in the franchise’s growth algorithm. Recent quarters confirm the level—$12.0–12.5B of revenue and mid-teens to 20% net margins—but year-over-year revenue growth has already slowed to roughly 5%, and the $10.6B of operating cash flow in 2025 is the cash expression of peak underwriting plus investment income, not a new baseline that compounds at the same rate.
At $376 the stock trades 13.7× trailing earnings, 2.62× book, and 1.77× sales against a fortress balance sheet ($300M debt, 0.9% debt-to-equity, $32.9B equity) and a 19% ROE. Those multiples are not punitive for a 19% ROE insurer in absolute terms, yet they are being applied to earnings that sit well above mid-cycle. Normalize NI back toward $4.5–5.0B—still a historically strong outcome—and the effective multiple expands into the mid-to-high teens while the 2.6× book multiple leaves little room for the combined-ratio mean reversion that every prior hard market has eventually delivered. Insider activity is pure option-exercise-and-sale noise; it neither confirms nor contradicts the fundamental picture.
The cleanest bull counter-argument is that the hard-market runway and the structural lift in investment income are still under-discounted, so 13.7× is actually a trough multiple on earnings that can grind higher for another two or three years. A smart opponent would also note the 15.6% payout ratio and low 1.2% yield leave ample capacity for buybacks that can offset multiple compression. I weigh that less heavily because revenue is already decelerating, catastrophe experience in 2025 looks benign relative to history, and the valuation synthesis fair-value cluster around $300–310 already embeds several years of above-average profitability. Paying a 20%+ premium to that cluster for duration of the cycle is a bet on continued perfection, not on the durability of the moat itself.
I would flip to a constructive stance if the next two quarters deliver mid-single-digit premium growth with combined ratios still in the low 90s and no material reserve strengthening, or if a clear multi-year pricing announcement in commercial lines pushes forward earnings power above $7B without a corresponding multiple contraction. A decisive break below 1.8× book on non-catastrophic news would also reset the risk/reward.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has grown steadily from $34.8B (2021) to $48.8B (2025), a ~9% CAGR, with net income expanding from $3.66B to $6.29B and FCF from $7.27B to $10.61B. OCF/NI at 2.07x and negative accruals (-3.2% of assets) point to conservative, cash-backed earnings - unusual quality for a P&C insurer where reserve accounting can hide sins. The Altman Z of 1.3 flagged as 'distress' is a false alarm: Z-scores are calibrated for industrials, not insurers whose balance sheets are dominated by policyholder liabilities and investment portfolios by design.
Verify before trusting this (5)
- Combined ratio trend and reserve development (favorable vs adverse) in the 10-K
- Investment portfolio credit quality and duration mismatch vs liabilities
- Reinsurance program adequacy and PML for major CAT scenarios
- Whether the 2024-2025 earnings jump reflects sustainable pricing or transient reserve releases
- Capital adequacy ratios (RBC) and dividend/buyback capacity from statutory entities
The composite fair value pins deserved price at $297.63, with the signal-adjusted number at $307.45 - both roughly 18-19% below the $377.30 quote. Even giving credit for genuinely strong earnings quality and disciplined buybacks (which argues for a modest premium over the anchored-PE mark), a fair deserved value sits in the $310-330 range. That still leaves the current price 15-20% too high. What is baked in: continued hard-market pricing, benign catastrophe experience, and mid-teens ROE sustaining a 1.2x+ book multiple. That is a plausible near-term path, not a heroic one, but P&C is cyclical - rates soften, CAT loads mount, and multiples compress. Paying a full-cycle premium at what may be a peak-cycle earnings print is the classic P&C mistake. This is a good business the market already understands; the mispricing, if any, runs the wrong way.
Verify before trusting this (5)
- Combined ratio trajectory and CAT load assumptions in latest 10-Q
- Reserve development trends - favorable or adverse
- Rate change % by segment in Business Insurance and Personal Lines
- Buyback pace and remaining authorization
- Management commentary on pricing cycle stage
The macro tape is mildly risk-on (regime score +47, VIX 15.5, S&P near highs) and that regime has been building for six days. But TRV's 0.46 beta means the tape barely touches it either way - risk-on rallies do not lift this name much, and risk-off tantrums do not maul it. So the market-wide tailwind lands soft. What actually presses on TRV is its narrative: a moderate-intensity, moderate-durability 'fortress insurer / steady compounder' story that is currently intact and being validated by 8.6% revenue CAGR and low volatility. Momentum is strong-positive and the stock is up 2.66% in a week, drawing momentum-investor attention per the Zacks-style flow. There is no narrative crack in the news - the flow is benign and mildly favorable. The bear case (priced for perfection at 1.23x book, cat losses rising, AI disrupting the agent model) is a latent risk but not currently being pressed by the tape or by news flow. Analyst tone was not provided but nothing in the flow suggests target cuts. Net: a low-key positive press - the story is working, momentum is being noticed, and no macro or narrative force is currently pushing against it. Not decisive, because low-beta defensives do not get euphoric bids in risk-on tapes; they just quietly drift up.
Verify before trusting this (4)
- Any hurricane / catastrophe loss headlines that would instantly activate the dormant bear narrative
- Analyst target revisions - are sell-side targets still chasing the price higher, or starting to lag?
- Peer P&C insurer earnings tone - a Chubb or Progressive miss would rotate sentiment across the group
- Whether the momentum flow persists or fades - a stall would remove the current bid
This lens hasn't been run for this ticker yet.
Prediction unavailable. valuation-synthesis has no result for TRV — the prediction needs its fair-value anchors.